Real-world evidence in achondroplasia: considerations for a standardized data set.

Achondroplasia Growth Quality of life Rare disease Real-world data Real-world evidence Registry

Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
26 06 2023
Historique:
received: 29 06 2022
accepted: 04 06 2023
medline: 28 6 2023
pubmed: 27 6 2023
entrez: 26 6 2023
Statut: epublish

Résumé

Collection of real-world evidence (RWE) is important in achondroplasia. Development of a prospective, shared, international resource that follows the principles of findability, accessibility, interoperability, and reuse of digital assets, and that captures long-term, high-quality data, would improve understanding of the natural history of achondroplasia, quality of life, and related outcomes. The Europe, Middle East, and Africa (EMEA) Achondroplasia Steering Committee comprises a multidisciplinary team of 17 clinical experts and 3 advocacy organization representatives. The committee undertook an exercise to identify essential data elements for a standardized prospective registry to study the natural history of achondroplasia and related outcomes. A range of RWE on achondroplasia is being collected at EMEA centres. Whereas commonalities exist, the data elements, methods used to collect and store them, and frequency of collection vary. The topics considered most important for collection were auxological measures, sleep studies, quality of life, and neurological manifestations. Data considered essential for a prospective registry were grouped into six categories: demographics; diagnosis and patient measurements; medical issues; investigations and surgical events; medications; and outcomes possibly associated with achondroplasia treatments. Long-term, high-quality data are needed for this rare, multifaceted condition. Establishing registries that collect predefined data elements across age spans will provide contemporaneous prospective and longitudinal information and will be useful to improve clinical decision-making and management. It should be feasible to collect a minimum dataset with the flexibility to include country-specific criteria and pool data across countries to examine clinical outcomes associated with achondroplasia and different therapeutic approaches.

Sections du résumé

BACKGROUND
Collection of real-world evidence (RWE) is important in achondroplasia. Development of a prospective, shared, international resource that follows the principles of findability, accessibility, interoperability, and reuse of digital assets, and that captures long-term, high-quality data, would improve understanding of the natural history of achondroplasia, quality of life, and related outcomes.
METHODS
The Europe, Middle East, and Africa (EMEA) Achondroplasia Steering Committee comprises a multidisciplinary team of 17 clinical experts and 3 advocacy organization representatives. The committee undertook an exercise to identify essential data elements for a standardized prospective registry to study the natural history of achondroplasia and related outcomes.
RESULTS
A range of RWE on achondroplasia is being collected at EMEA centres. Whereas commonalities exist, the data elements, methods used to collect and store them, and frequency of collection vary. The topics considered most important for collection were auxological measures, sleep studies, quality of life, and neurological manifestations. Data considered essential for a prospective registry were grouped into six categories: demographics; diagnosis and patient measurements; medical issues; investigations and surgical events; medications; and outcomes possibly associated with achondroplasia treatments.
CONCLUSIONS
Long-term, high-quality data are needed for this rare, multifaceted condition. Establishing registries that collect predefined data elements across age spans will provide contemporaneous prospective and longitudinal information and will be useful to improve clinical decision-making and management. It should be feasible to collect a minimum dataset with the flexibility to include country-specific criteria and pool data across countries to examine clinical outcomes associated with achondroplasia and different therapeutic approaches.

Identifiants

pubmed: 37365619
doi: 10.1186/s13023-023-02755-w
pii: 10.1186/s13023-023-02755-w
pmc: PMC10294372
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

166

Informations de copyright

© 2023. The Author(s).

Références

Perspect Clin Res. 2021 Jul-Sep;12(3):171-174
pubmed: 34386383
Birth Defects Res A Clin Mol Teratol. 2014 Apr;100(4):247-9
pubmed: 24677650
Lancet. 2007 Jul 14;370(9582):162-172
pubmed: 17630040
J Pediatr. 2009 Oct;155(4):510-5
pubmed: 19608200
Disabil Rehabil. 2022 Oct;44(21):6166-6178
pubmed: 34403286
Pediatr Endocrinol Rev. 2017 Nov;15(Suppl 1):109-118
pubmed: 29292874
Curr Opin Pediatr. 2007 Feb;19(1):32-7
pubmed: 17224659
Appl Clin Genet. 2014 Jun 24;7:117-25
pubmed: 25053890
Am J Med Genet A. 2019 Sep;179(9):1791-1798
pubmed: 31294928
Orphanet J Rare Dis. 2021 Apr 7;16(1):156
pubmed: 33827611
N Engl J Med. 2016 Dec 8;375(23):2293-2297
pubmed: 27959688
Orphanet J Rare Dis. 2019 Aug 9;14(1):194
pubmed: 31399110
Paediatr Respir Rev. 2013 Dec;14(4):250-5
pubmed: 23523391
Am J Hum Genet. 1987 Sep;41(3):454-64
pubmed: 3631079
Pediatrics. 2020 Jun;145(6):
pubmed: 32457214
Orphanet J Rare Dis. 2018 Sep 5;13(1):154
pubmed: 30185208
Orphanet J Rare Dis. 2019 Jan 3;14(1):1
pubmed: 30606190
Arch Dis Child. 2012 Feb;97(2):129-34
pubmed: 21460402
Am J Med Genet A. 2020 Nov;182(11):2540-2551
pubmed: 32864841
Am J Med Genet A. 2020 Oct;182(10):2297-2316
pubmed: 32803853
Pediatrics. 2005 Sep;116(3):771-83
pubmed: 16140722
Arch Dis Child. 2021 Feb;106(2):180-184
pubmed: 32883660
Dev Med Child Neurol. 2011 Oct;53(10):944-50
pubmed: 21838822
J Med Genet. 1998 Sep;35(9):705-12
pubmed: 9733026
Clin Genet. 2020 Jan;97(1):179-197
pubmed: 30916780
Genet Med. 2021 Aug;23(8):1498-1505
pubmed: 34006999
J Clin Nurs. 2014 Nov;23(21-22):3045-56
pubmed: 25453127
J Neurosurg Pediatr. 2021 Jun 4;:1-7
pubmed: 34087800

Auteurs

Yasemin Alanay (Y)

Pediatric Genetics, Department of Pediatrics, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Kayisdagi Cad. No:32, Atasehir, 34684, Istanbul, Turkey. yasemin.alanay@acibadem.edu.tr.

Klaus Mohnike (K)

Department of Pediatrics, Otto-von-Guericke-University, Magdeburg, Germany.

Ola Nilsson (O)

Division of Pediatric Endocrinology and Center for Molecular Medicine, Department of Women's and Children's Health, Karolinska Institute and University Hospital, Stockholm, Sweden.
Department of Medical Sciences, Örebro University, Örebro, Sweden.
Department of Pediatrics, Örebro University Hospital, Örebro, Sweden.

Inês Alves (I)

ANDO Portugal, Évora, Portugal.

Moeenaldeen AlSayed (M)

Department of Medical Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.

Natasha M Appelman-Dijkstra (NM)

Department of Internal Medicine, Division Endocrinology and Center for Bone Quality, Leiden University Medical Center, Leiden, The Netherlands.

Genevieve Baujat (G)

Hôpital Necker Enfants Malades AP-HP, Paris, France.

Tawfeg Ben-Omran (T)

Genetic and Genomic Medicine Division, Sidra Medicine and Hamad Medical Corporation, Doha, Qatar.

Sandra Breyer (S)

Department of Paediatrics, UKE Hamburg-Eppendorf, Hamburg, Germany.

Valerie Cormier-Daire (V)

Hôpital Necker Enfants Malades AP-HP, Paris, France.
Reference Center for Skeletal Dysplasia, Imagine Institute, Paris Cité University, Paris, France.

Pernille Axél Gregersen (PA)

Department of Clinical Genetics and Centre for Rare Diseases, Aarhus University Hospital, Aarhus, Denmark.

Encarna Guillén-Navarro (E)

Medical Genetics Section, Department of Paediatrics, Virgen de la Arrixaca University Clinical Hospital, IMIB-Arrixaca, Faculty of Medicine, University of Murcia (UMU), Murcia, Spain.

Wolfgang Högler (W)

Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz, Linz, Austria.

Mohamad Maghnie (M)

Department of Paediatrics, IRCCS Istituto Giannna Gaslini, Genoa, Italy.
Department of Neuroscience, Rehabilitation, Ophthalmology Genetics, Maternal and Child-Health, University of Genova, Genoa, Italy.

Swati Mukherjee (S)

BioMarin (UK) Limited, London, UK.

Shelda Cohen (S)

BioMarin (UK) Limited, London, UK.

Jeanne Pimenta (J)

BioMarin (UK) Limited, London, UK.

Angelo Selicorni (A)

Pediatric Unit ASST Lariana, Mariani Center for Fragile Child, Como, Italy.

J Oliver Semler (JO)

Faculty of Medicine, University of Cologne, Cologne, Germany.
Department of Pediatrics, University Hospital Cologne, Cologne, Germany.

Sabine Sigaudy (S)

Département de Génétique Médicale, Hôpital Timone Enfant, Marseille, France.

Dmitry Popkov (D)

National Ilizarov Research Center for Traumatology and Orthopaedics, Kurgan, Russia.

Ian Sabir (I)

BioMarin (UK) Limited, London, UK.

Susana Noval (S)

Fundación ALPE Acondroplasia, Asturias, Spain.

Marco Sessa (M)

Associazione per I'Informazione e lo Studio dell'Acondroplasia (AISAC), Milan, Italy.

Melita Irving (M)

Guy's and St. Thomas' NHS Foundation Trust, Evelina Children's Hospital, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH